Therapeutic Asset Ratings

831 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Polyiclc Locally Advanced Urothelial Carcinoma	Mayo Clinic	P1/2	CCC (53)
SONALA-001 Progressive Glioblastoma	Mayo Clinic	P1/2	CCC (53)
DARATUMUMAB Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Mayo Clinic	P2	CCC (52)
Decitabine Lymphoma	Mayo Clinic	P2	CCC (52)
Durvalumab Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Mayo Clinic	P2	CCC (52)
FILGRASTIM Hepatocellular Carcinoma	Mayo Clinic	P2	CCC (52)
Futibatinib Hepatocellular Carcinoma	Mayo Clinic	P2	CCC (52)
Gdc-0449 Pancreatic Ductal Adenocarcinoma	Mayo Clinic	P2	CCC (52)
PITTSBURGH COMPOUND B UNLABELLED Parkinson Disease	Mayo Clinic	P2	CCC (52)
Cyclophosphamide Recurrent Primary Peritoneal Carcinosarcoma	Mayo Clinic	P1/2	CCC (52)
Eflornithine Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype	Mayo Clinic	P1/2	CCC (52)
Polyiclc Locally Advanced Renal Cell Carcinoma	Mayo Clinic	P1/2	CCC (52)
Polypepi1018 Colorectal Cancer	Mayo Clinic	P1/2	CCC (52)
Ifosfamide Chronic Myelomonocytic Leukemia	Mayo Clinic	P2	CCC (51)
plx038 Fallopian Tube Carcinoma	Mayo Clinic	P2	CCC (50)
plx038 Ovarian Carcinoma	Mayo Clinic	P2	CCC (50)
plx038 Primary Peritoneal Carcinoma	Mayo Clinic	P2	CCC (50)
plx038 Fallopian Tube Cancer	Mayo Clinic	P2	CCC (50)
plx038 Ovarian Cancer	Mayo Clinic	P2	CCC (50)
Eflornithine IDH-Wildtype Glioblastoma	Mayo Clinic	P1/2	CCC (50)
Epirubicin Unresectable Malignant Solid Neoplasm	Mayo Clinic	P1/2	CCC (50)
Pembrolizumab Unresectable Malignant Solid Neoplasm	Mayo Clinic	P1/2	CCC (50)
Efineptakin Alfa High Grade Astrocytic Tumor	Mayo Clinic	P2	CCC (49)
Efineptakin Alfa IDH-Wildtype Glioblastoma	Mayo Clinic	P2	CCC (49)
Efineptakin Alfa Gliosarcoma	Mayo Clinic	P2	CCC (49)

Showing 476 to 500 of 831 assets

PreviousPage 20 of 34Next